CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向白血病干细胞的脂质体纳米免疫疗法通过沉默 B 细胞淋巴瘤 2 逆转免疫逃逸并抑制融合癌蛋白驱动的急性髓系白血病

Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silen

以双特异性抗体 XmAb 18968 靶向 CD38 治疗复发/难治性急性髓系白血病和 T 细胞急性淋巴细胞白血病患者

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia

通过免疫突触稳定受体增强 CAR 和 TCR 介导的癌症靶向

Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor.

具有 CD38(-)CD73(-)Tim-3(-)HLA-DR(+) 表型的 CAR-T 细胞预测 tisagenlecleucel 治疗 B 细胞前体 ALL 的疗效

CAR-T cells with the CD38(-)CD73(-)Tim-3(-)HLA-DR(+) phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.

CCR4 表达定义了 T 细胞急性淋巴细胞白血病的一个可靶向亚群

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

BNT162b2 mRNA 疫苗接种影响滤泡性淋巴瘤和慢性淋巴细胞白血病患者的肠道微生物组组成

BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia.

LLT1 过表达导致同种异体 NK 抵抗并促进增强型通用 CAR-T 细胞的生成

LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells.

根据这些结果，LLT1 过表达增强了 UCAR-T 细胞的活性并防止同种异体排斥反应，为通用型 CAR-T 细胞疗法的开发提供了重要见解。

CD38 特异性 CAR 整合到 CD38 基因座并由不同启动子驱动，导致 T 细胞和 NK 细胞具有不同的抗肿瘤活性

CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.

NK 细胞模拟纳米颗粒能够主动靶向并杀死急性髓系白血病细胞

Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells.

基于 CAR.CD123-NK 细胞的安全有效现货型免疫治疗用于急性髓系白血病

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.

我们的数据表明，基于 CAR.CD123-NK 细胞的创新型即用型治疗策略具有可行性，其特点是疗效显著，且与 CAR.CD123-T 细胞相比安全性更好。这些发现不仅为难治/耐药 AML 患者的治疗开辟了一个新的有趣前景，也为进一步研究 CAR-NK 细胞在那些以传统 T 效应细胞极难靶向为特征的其他癌症中的应用开辟了前景。